Frontiers in Immunology (May 2021)
Transcriptomic Signature Differences Between SARS-CoV-2 and Influenza Virus Infected Patients
- Stéphanie Bibert,
- Nicolas Guex,
- Joao Lourenco,
- Thomas Brahier,
- Matthaios Papadimitriou-Olivgeris,
- Lauro Damonti,
- Lauro Damonti,
- Oriol Manuel,
- Robin Liechti,
- Robin Liechti,
- Lou Götz,
- Lou Götz,
- Jonathan Tschopp,
- Mathieu Quinodoz,
- Mathieu Quinodoz,
- Mathieu Quinodoz,
- Peter Vollenweider,
- Jean-Luc Pagani,
- Mauro Oddo,
- Olivier Hügli,
- Frédéric Lamoth,
- Frédéric Lamoth,
- Véronique Erard,
- Cathy Voide,
- Mauro Delorenzi,
- Mauro Delorenzi,
- Nathalie Rufer,
- Fabio Candotti,
- Carlo Rivolta,
- Carlo Rivolta,
- Carlo Rivolta,
- Noémie Boillat-Blanco,
- Pierre-Yves Bochud,
- the RegCOVID Study Group,
- Bochud Pierre-Yves,
- Desgranges Florian,
- Filippidis Paraskevas,
- Guéry Benoit,
- Haefliger David,
- Kampouri Eleftheria-Evdokia,
- Manuel Oriol,
- Munting Aline,
- Pagani Jean-Luc,
- Papadimitriou-Olivgeris Matthaios,
- Regina Jean,
- Rochat-Stettler Laurence,
- Suttels Veronique,
- Tadini Eliana,
- Tschopp Jonathan,
- Van Singer Mathias,
- Viala Benjamin,
- Vollenweider Peter
Affiliations
- Stéphanie Bibert
- Infectious Diseases Service, Department of Medicine, University Hospital and University of Lausanne, Lausanne, Switzerland
- Nicolas Guex
- Bioinformatics Competence Center, University of Lausanne, Lausanne, Switzerland
- Joao Lourenco
- SIB Swiss Institute of Bioinformatics and Department of Fundamenal Oncology, University of Lausanne, Lausanne, Switzerland
- Thomas Brahier
- Infectious Diseases Service, Department of Medicine, University Hospital and University of Lausanne, Lausanne, Switzerland
- Matthaios Papadimitriou-Olivgeris
- Infectious Diseases Service, Department of Medicine, University Hospital and University of Lausanne, Lausanne, Switzerland
- Lauro Damonti
- Infectious Diseases Service, Department of Medicine, University Hospital and University of Lausanne, Lausanne, Switzerland
- Lauro Damonti
- Department of Infectious Diseases, Bern University Hospital, Bern, Switzerland
- Oriol Manuel
- Infectious Diseases Service and Transplantation Center, Department of Medicine, University Hospital and University of Lausanne, Lausanne, Switzerland
- Robin Liechti
- Bioinformatics Competence Center, University of Lausanne, Lausanne, Switzerland
- Robin Liechti
- SIB Swiss Institute of Bioinformatics and Department of Fundamenal Oncology, University of Lausanne, Lausanne, Switzerland
- Lou Götz
- Bioinformatics Competence Center, University of Lausanne, Lausanne, Switzerland
- Lou Götz
- SIB Swiss Institute of Bioinformatics and Department of Fundamenal Oncology, University of Lausanne, Lausanne, Switzerland
- Jonathan Tschopp
- Infectious Diseases Service, Department of Medicine, University Hospital and University of Lausanne, Lausanne, Switzerland
- Mathieu Quinodoz
- Institute of Molecular and Clinical Ophthalmology Basel (IOB), Basel, Switzerland
- Mathieu Quinodoz
- Department of Ophthalmology, University Hospital Basel, Basel, Switzerland
- Mathieu Quinodoz
- Department of Genetics and Genome Biology, University of Leicester, Leicester, United Kingdom
- Peter Vollenweider
- Internal Medicine Service, Department of Medicine, University Hospital and University of Lausanne, Lausanne, Switzerland
- Jean-Luc Pagani
- 0Department of Adult Intensive Care Medicine, University Hospital and University of Lausanne, Lausanne, Switzerland
- Mauro Oddo
- 0Department of Adult Intensive Care Medicine, University Hospital and University of Lausanne, Lausanne, Switzerland
- Olivier Hügli
- 1Emergency Department, University Hospital and University of Lausanne, Lausanne, Switzerland
- Frédéric Lamoth
- Infectious Diseases Service, Department of Medicine, University Hospital and University of Lausanne, Lausanne, Switzerland
- Frédéric Lamoth
- 2Department of Laboratory Medicine, Institute of Microbiology, University Hospital and University of Lausanne, Lausanne, Switzerland
- Véronique Erard
- 3Clinique de Médecine et spécialités, Infectiologie, Hôpital Fribourgeois-Fribourg, Fribourg, Switzerland
- Cathy Voide
- 4Department of Infectious Diseases, Central Institute, Valais Hospital, Sion, Switzerland
- Mauro Delorenzi
- SIB Swiss Institute of Bioinformatics and Department of Fundamenal Oncology, University of Lausanne, Lausanne, Switzerland
- Mauro Delorenzi
- 5Department of Oncology, University Hospital and University of Lausanne, Epalinges, Switzerland
- Nathalie Rufer
- 5Department of Oncology, University Hospital and University of Lausanne, Epalinges, Switzerland
- Fabio Candotti
- 6Division of Immunology and Allergy, University Hospital and University of Lausanne, Lausanne, Switzerland
- Carlo Rivolta
- Institute of Molecular and Clinical Ophthalmology Basel (IOB), Basel, Switzerland
- Carlo Rivolta
- Department of Ophthalmology, University Hospital Basel, Basel, Switzerland
- Carlo Rivolta
- Department of Genetics and Genome Biology, University of Leicester, Leicester, United Kingdom
- Noémie Boillat-Blanco
- Infectious Diseases Service, Department of Medicine, University Hospital and University of Lausanne, Lausanne, Switzerland
- Pierre-Yves Bochud
- Infectious Diseases Service, Department of Medicine, University Hospital and University of Lausanne, Lausanne, Switzerland
- the RegCOVID Study Group
- Bochud Pierre-Yves
- Desgranges Florian
- Filippidis Paraskevas
- Guéry Benoit
- Haefliger David
- Kampouri Eleftheria-Evdokia
- Manuel Oriol
- Munting Aline
- Pagani Jean-Luc
- Papadimitriou-Olivgeris Matthaios
- Regina Jean
- Rochat-Stettler Laurence
- Suttels Veronique
- Tadini Eliana
- Tschopp Jonathan
- Van Singer Mathias
- Viala Benjamin
- Vollenweider Peter
- DOI
- https://doi.org/10.3389/fimmu.2021.666163
- Journal volume & issue
-
Vol. 12
Abstract
The reason why most individuals with COVID-19 have relatively limited symptoms while other develop respiratory distress with life-threatening complications remains unknown. Increasing evidence suggests that COVID-19 associated adverse outcomes mainly rely on dysregulated immunity. Here, we compared transcriptomic profiles of blood cells from 103 patients with different severity levels of COVID-19 with that of 27 healthy and 22 influenza-infected individuals. Data provided a complete overview of SARS-CoV-2-induced immune signature, including a dramatic defect in IFN responses, a reduction of toxicity-related molecules in NK cells, an increased degranulation of neutrophils, a dysregulation of T cells, a dramatic increase in B cell function and immunoglobulin production, as well as an important over-expression of genes involved in metabolism and cell cycle in patients infected with SARS-CoV-2 compared to those infected with influenza viruses. These features also differed according to COVID-19 severity. Overall and specific gene expression patterns across groups can be visualized on an interactive website (https://bix.unil.ch/covid/). Collectively, these transcriptomic host responses to SARS-CoV-2 infection are discussed in the context of current studies, thereby improving our understanding of COVID-19 pathogenesis and shaping the severity level of COVID-19.
Keywords